Press Releases Ypsomed Group

Burgdorf – Ypsomed has collaborated with Biocon, an emerging global biopharmaceutical company headquartered in India, to customise its reusable YpsoPen for use with Biocon’s insulin cartridges. This customised reusable pen will be marketed by Biocon as INSUPen Pro™ in Malaysia.

Biocon has set up one of Asia’s largest integrated Insulin manufacturing facility in Malaysia and has introduced its Insugen® and INSUPen Pro™ brands in the local market recently. Ypsomed’s high quality reusable pen compliments Biocon’s Insulins product portfolio and enables Biocon to further address the growing needs of people with diabetes in Malaysia.

“The introduction of the INSUPen Pro™ in Malaysia through its partnership with Biocon is yet another important milestone in Ypsomed’s journey to provide patients across the globe with access to high quality injection systems.”

summarises CEO Simon Michel this success.

According to estimates by the International Diabetes Federation, over 3.3 million people are affected by diabetes in Malaysia. By 2020, this number will increase to over 4.5 million people and present a major burden for the health system. Biocon's locally manufactured recombinant human insulin combined with the INSUPen Pro™ device will offer the Malaysian people a convenient and high quality treatment option to tackle the growing incidence of diabetes.

Thomas Kutt
Head of Investor Relations
Ypsomed Holding AG

Go back